A Phase I, Randomized, Double-Blind Study to Assess the Effects of Repeat Oral Dosing of Ketoconazole on the Pharmacokinetics of Repeat Oral Dosing of Casopitant in Healthy Subjects
GlaxoSmithKline
Description
Casopitant may affect liver enzymes that metabolize ketoconazole. This study is designed to test the safety and the extent of the Casopitant affect on ketoconazole levels in healthy human subjects.
Citations (0)
No citations found
It looks like this dataset has no citations.
Mentions (0)
No mentions found
It looks like this dataset has not been mentioned in any sources.
Metrics Over Time
Publication Details
DOI
Publisher
Vivli
License
Study data may be accessed by completing a request form at https://vivli.org. It will then be reviewed according to the data contributor’s governance policy, see https://vivli.org/members/ourmembers/ for Vivli member’s review process. If approved, use of the data is governed by the data use agreement at https://vivli.org/resources/vivli-data-use-agreement/
Subfield
Pharmacology
Field
Medicine
Domain
Health Sciences
Confidence Score
49%
Source
Scholar Data Model
Keywords
Conditions: Nausea and Vomiting, Chemotherapy-InducedInterventions: Casopitant 150 mgInterventions: KetoconazoleInterventions: Casopitant 150 mg matching placeboInterventions: Casopitant 50 mgInterventions: Casopitant 50 mg matching placebo